Dosing at a site of the cholesterol powder. Oral or praziquantel is unstable in water, body fluids, and urine and is absorbed in methanol and ethanol. Oral is not active within the physiological pH range.

XENICAL® (orlistat) is available for cost administration as a double-layered transient gelatin capsule. The dark brown beads are prisms of the active ingredient, orlistat, suspended orlistat, methyl-30-cyclohexene-1-carboxylic acid, and the yellow gelatin capsule. The dose is split with a 2-day supply of the active ingredient, orlistat, suspended in hydroxypropyl methylcellulose, hydroxypropyl cellulose, and gelatin. The dark brown gelatin capsule contains a yellow, reddish-brown, basic yellow 11, basic red 1, basic red 4, basic violet 1, and ferric oxide yellow. The yellow gelatin capsule contains a yellow, reddish-brown, basic yellow 11, basic red 1, basic red 4, basic violet 1, and ferric oxide yellow. The enteric-coated capsule is resistant to the pH of the gastrointestinal tract. The enteric-coated capsule maintains the integrity of the drug during passage through the upper gastrointestinal tract, allowing the drug to be released only in the small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The dissolved orlistat is absorbed into the intestinal tract where it acts on dietary fat to prevent its absorption. The doses are absorbed into the nutrient and passed through the body without being metabolized. The active ingredient, orlistat, is generally not measurable in plasma and excretion of the unabsorbed drug was found to be the major route of elimination. The absolute bioavailability of intact orlistat in plasma was sporadic and concentrations were low (<10 ng/mL or 0.02 µM), without evidence of accumulation, and consistent with minimal absorption.

Pharmacokinetics
Systemic exposure to orlistat is extensive. Following oral dosing with 280 mg (three capsules) of XENICAL orlistat 60 mg and 120 mg (two capsules) of XENICAL, the systemic exposure increased proportionally with increasing dose. Following oral dosing with 280 mg (three capsules) of XENICAL orlistat 60 mg and 120 mg (two capsules) of XENICAL, the systemic exposure increased proportionally with increasing dose. The systemic exposure of orlistat is dependent on the dose of the active ingredient, orlistat, in the capsules. The systemic exposure of orlistat in plasma was observed and concentrations were low (<10 ng/mL or 0.02 µM), without evidence of accumulation, and consistent with minimal absorption.

Metabolism
Orlistat is metabolized by the intestinal wall. Based on in vitro and in vivo studies, metabolites of orlistat are orlistat, methyl-30-cyclohexene-1-carboxylic acid, and the yellow gelatin capsule. The dose is split with a 2-day supply of the active ingredient, orlistat, suspended in hydroxypropyl methylcellulose, hydroxypropyl cellulose, and gelatin. The dark brown gelatin capsule contains a yellow, reddish-brown, basic yellow 11, basic red 1, basic red 4, basic violet 1, and ferric oxide yellow. The yellow gelatin capsule contains a yellow, reddish-brown, basic yellow 11, basic red 1, basic red 4, basic violet 1, and ferric oxide yellow. The enteric-coated capsule is resistant to the pH of the gastrointestinal tract. The enteric-coated capsule maintains the integrity of the drug during passage through the upper gastrointestinal tract, allowing the drug to be released only in the small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The dissolved orlistat is absorbed into the intestinal tract where it acts on dietary fat to prevent its absorption. The doses are absorbed into the nutrient and passed through the body without being metabolized. The active ingredient, orlistat, is generally not measurable in plasma and excretion of the unabsorbed drug was found to be the major route of elimination. The absolute bioavailability of intact orlistat in plasma was sporadic and concentrations were low (<10 ng/mL or 0.02 µM), without evidence of accumulation, and consistent with minimal absorption.

Pharmacokinetics
Systemic exposure to orlistat is extensive. Following oral dosing with 280 mg (three capsules) of XENICAL orlistat 60 mg and 120 mg (two capsules) of XENICAL, the systemic exposure increased proportionally with increasing dose. Following oral dosing with 280 mg (three capsules) of XENICAL orlistat 60 mg and 120 mg (two capsules) of XENICAL, the systemic exposure increased proportionally with increasing dose. The systemic exposure of orlistat is dependent on the dose of the active ingredient, orlistat, in the capsules. The systemic exposure of orlistat in plasma was observed and concentrations were low (<10 ng/mL or 0.02 µM), without evidence of accumulation, and consistent with minimal absorption.

Metabolism
Orlistat is metabolized by the intestinal wall. Based on in vitro and in vivo studies, metabolites of orlistat are orlistat, methyl-30-cyclohexene-1-carboxylic acid, and the yellow gelatin capsule. The dose is split with a 2-day supply of the active ingredient, orlistat, suspended in hydroxypropyl methylcellulose, hydroxypropyl cellulose, and gelatin. The dark brown gelatin capsule contains a yellow, reddish-brown, basic yellow 11, basic red 1, basic red 4, basic violet 1, and ferric oxide yellow. The yellow gelatin capsule contains a yellow, reddish-brown, basic yellow 11, basic red 1, basic red 4, basic violet 1, and ferric oxide yellow. The enteric-coated capsule is resistant to the pH of the gastrointestinal tract. The enteric-coated capsule maintains the integrity of the drug during passage through the upper gastrointestinal tract, allowing the drug to be released only in the small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The dissolved orlistat is absorbed into the intestinal tract where it acts on dietary fat to prevent its absorption. The doses are absorbed into the nutrient and passed through the body without being metabolized. The active ingredient, orlistat, is generally not measurable in plasma and excretion of the unabsorbed drug was found to be the major route of elimination. The absolute bioavailability of intact orlistat in plasma was sporadic and concentrations were low (<10 ng/mL or 0.02 µM), without evidence of accumulation, and consistent with minimal absorption.

Pharmacokinetics
Systemic exposure to orlistat is extensive. Following oral dosing with 280 mg (three capsules) of XENICAL orlistat 60 mg and 120 mg (two capsules) of XENICAL, the systemic exposure increased proportionally with increasing dose. Following oral dosing with 280 mg (three capsules) of XENICAL orlistat 60 mg and 120 mg (two capsules) of XENICAL, the systemic exposure increased proportionally with increasing dose. The systemic exposure of orlistat is dependent on the dose of the active ingredient, orlistat, in the capsules. The systemic exposure of orlistat in plasma was observed and concentrations were low (<10 ng/mL or 0.02 µM), without evidence of accumulation, and consistent with minimal absorption.

Metabolism
Orlistat is metabolized by the intestinal wall. Based on in vitro and in vivo studies, metabolites of orlistat are orlistat, methyl-30-cyclohexene-1-carboxylic acid, and the yellow gelatin capsule. The dose is split with a 2-day supply of the active ingredient, orlistat, suspended in hydroxypropyl methylcellulose, hydroxypropyl cellulose, and gelatin. The dark brown gelatin capsule contains a yellow, reddish-brown, basic yellow 11, basic red 1, basic red 4, basic violet 1, and ferric oxide yellow. The yellow gelatin capsule contains a yellow, reddish-brown, basic yellow 11, basic red 1, basic red 4, basic violet 1, and ferric oxide yellow. The enteric-coated capsule is resistant to the pH of the gastrointestinal tract. The enteric-coated capsule maintains the integrity of the drug during passage through the upper gastrointestinal tract, allowing the drug to be released only in the small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The dissolved orlistat is absorbed into the intestinal tract where it acts on dietary fat to prevent its absorption. The doses are absorbed into the nutrient and passed through the body without being metabolized. The active ingredient, orlistat, is generally not measurable in plasma and excretion of the unabsorbed drug was found to be the major route of elimination. The absolute bioavailability of intact orlistat in plasma was sporadic and concentrations were low (<10 ng/mL or 0.02 µM), without evidence of accumulation, and consistent with minimal absorption.

Pharmacokinetics
Systemic exposure to orlistat is extensive. Following oral dosing with 280 mg (three capsules) of XENICAL orlistat 60 mg and 120 mg (two capsules) of XENICAL, the systemic exposure increased proportionally with increasing dose. Following oral dosing with 280 mg (three capsules) of XENICAL orlistat 60 mg and 120 mg (two capsules) of XENICAL, the systemic exposure increased proportionally with increasing dose. The systemic exposure of orlistat is dependent on the dose of the active ingredient, orlistat, in the capsules. The systemic exposure of orlistat in plasma was observed and concentrations were low (<10 ng/mL or 0.02 µM), without evidence of accumulation, and consistent with minimal absorption.

Metabolism
Orlistat is metabolized by the intestinal wall. Based on in vitro and in vivo studies, metabolites of orlistat are orlistat, methyl-30-cyclohexene-1-carboxylic acid, and the yellow gelatin capsule. The dose is split with a 2-day supply of the active ingredient, orlistat, suspended in hydroxypropyl methylcellulose, hydroxypropyl cellulose, and gelatin. The dark brown gelatin capsule contains a yellow, reddish-brown, basic yellow 11, basic red 1, basic red 4, basic violet 1, and ferric oxide yellow. The yellow gelatin capsule contains a yellow, reddish-brown, basic yellow 11, basic red 1, basic red 4, basic violet 1, and ferric oxide yellow. The enteric-coated capsule is resistant to the pH of the gastrointestinal tract. The enteric-coated capsule maintains the integrity of the drug during passage through the upper gastrointestinal tract, allowing the drug to be released only in the small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The dissolved orlistat is absorbed into the intestinal tract where it acts on dietary fat to prevent its absorption. The doses are absorbed into the nutrient and passed through the body without being metabolized. The active ingredient, orlistat, is generally not measurable in plasma and excretion of the unabsorbed drug was found to be the major route of elimination. The absolute bioavailability of intact orlistat in plasma was sporadic and concentrations were low (<10 ng/mL or 0.02 µM), without evidence of accumulation, and consistent with minimal absorption.
...which would have a BMI of 30.

...dyslipidemia).

...of type 2 diabetes.

...incidence of cholelithiasis was similar for XENICAL and placebo at similar amounts of weight loss.

...in a clinical trial of XENICAL for the

...Caution should be exercised when prescribing XENICAL to patients with a history of hyperoxaluria or

...report any symptoms of hepatic dysfunction (anorexia, pruritus, vitamin level on two or more consecutive visits during 1 and 2 years of therapy in studies in which

...Patients should be strongly encouraged to take a multivitamin supplement that contains fat-soluble

...Table 10  Incidence of Low Vitamin Values on Two or More Consecutive Visits (Pediatric Patients

...† Treatment designates placebo plus diet or XENICAL plus diet

...illustrates the percentage of adolescent patients on XENICAL and placebo who developed a low

...Body System/Adverse Even

...Central Nervous System

...Vaginitis

...Urinary Tract Infection 7.5 7.3 5.9 4.8

...Depression

...Hearing & Vestibular Disorders

......Von Willebrand Disease

......Addison Disease

......Peptic Ulcer Disease

......Pneumonia

......Hypothyroidism

......Thrombophlebitis

......Cholecystitis

......Hypertension

......Cholelithiasis

......Hepatitis

......Hemorrhoids

......Hematoma

......Forgetfulness

......Nausea

......Malaria

......Migraine

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis

......Hematoma

......Meningitis